During the past decade, Mercy Clinic - Cancer & Hematology conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 4 clinical trials were completed, i.e. on average, 57.1% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mercy Clinic - Cancer & Hematology" #1 sponsor was "Hoffmann-La Roche" with 2 trials, followed by "Alliance Foundation Trials, LLC." with 1 trials sponsored, "Egetis Therapeutics" with 1 trials sponsored, "Genentech, Inc." with 1 trials sponsored and "ImmunityBio, Inc." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mercy Clinic - Cancer & Hematology" #1 collaborator was "American Cancer Society, Inc." with 1 trials as a collaborator, "American Society of Clinical Oncology" with 1 trials as a collaborator, "Dana-Farber Cancer Institute" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Mercy Clinic - Cancer & Hematology" are "Colorectal Cancer" (2 trials), "Breast Cancer" (1 trials), "Carcinoma, Pancreatic Ductal" (1 trials), "Cervical Cancer" (1 trials) and "Chemotherapy-induced Peripheral Neuropathy" (1 trials). Many other conditions were trialed in "Mercy Clinic - Cancer & Hematology" in a lesser frequency.

Most popular intervention types in "Mercy Clinic - Cancer & Hematology" are "Drug" (8 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Gemcitabine" (2 trials), "Nab-paclitaxel" (2 trials), "paclitaxel" (2 trials), "Atezolizumab" (1 trials) and "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials). Other intervention names were less common.

The vast majority of trials in "Mercy Clinic - Cancer & Hematology" are 8 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Mercy Clinic - Cancer & Hematology". undefined are not yet recruiting, 1 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Mercy Clinic - Cancer & Hematology, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Mercy Clinic - Cancer & Hematology, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".